Summary
A total of 104 unselected, previously untreated patients with invasive stage III or IV ovarian cancer were operated on between 1977 and 1984. Nine patients were lost in follow-up, three died from non-malignant disease. Thirteen of the 92 eligible patients (15%) were observed to survive 5 years or longer. In the 13 long-term survivors, 4 had stage IV disease, 7 positive peritoneal cytology, 3 bowel resection, and 12 residual disease <2 cm after primary surgery. Retroperitoneal lymph nodes were involved in 6/9 cases. The majority of 5-year survivors (69%) received cis-platin-containing combination chemotherapy. 5/7 long-term survivors had positive second-look. At 5 years, life-quality in 9/13 patients who were free of disease, was high. It can be concluded that only patients with optimally resected stage III or IV ovarian cancer have a realistic chance of long-term survival. It is expected that increasing radicality in surgery for ovarian cancer together with platinum-based chemotherapy regimens may improve long-term survival in the future. In addition, further studies of new chemotherapeutic approaches are needed.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
American Joint Committee on Cancer (1988) Manual for staging of cancer, 3rd edn. Lippincott, Philadelphia
Barlow J, Lele S, Emrich L (1985) Long-term survival rates with various chemotherapeutic regimens in stages III and IV ovarian adenocarcinoma. Am J Obstet Gynecol 152:310–314
Burghardt E, Lahousen M, Stettner H (1989) The significance of pelvic and paraaortic lymphadenectomy in the operative treatment of ovarian cancer. In: Burghardt E, Monaghan J (eds) Operative treatment of ovarian cancer. Bailliere’s Clin Obstet Gynaecol vol 3, pp 157–165
Chen S (1987) Survival of ovarian carcinoma with and without lymph node metastasis. Gynecol Oncol 27:368–372
Copeland L, Gershenson D, Wharton T, Atkinson N, Sneige N, Edwards C, Rutledge F (1985) Microscopic disease at second-look laparotomy in advanced ovarian cancer. Cancer 55:472–478
Decker D (1983) Mayo clinic experience with epithelial ovarian cancer. Clin Obstet Gynaecol 10:337–356
Griffiths C, Parker L, Fuller A (1979) Role of cytoreductive surgical treatment in the management of advanced ovarian cancer. Cancer Treat Rep 63:235–240
Howell S, Zimm S, Markman M, Abramson I, Cleary S, Lucas W, Weiss R (1987) Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy. J Clin Oncol 5:1607–1612
Klein B, Falkson G, Smit C (1985) Advanced ovarian carcinoma — factors influencing survival. Cancer 55:1829–1834
Krag K, Canellos G, Griffiths C, Knapp R, Parker L, Welch W, Klatt M, Andersen J (1989) Predictive factors for long-term survival in patients with advanced ovarian cancer. Gynecol Oncol 34:88–93
Louie K, Ozols R, Myers C, Ostchega Y, Jenkins J, Howser D, Young R (1986) Long-term results of a cisplatin-containing combination chemotherapy regimen for the treatment of advanced ovarian carcinoma. J Clin Oncol 4:1579–1585
Piver, S (1984) Ovarian carcinoma. A decade of progress. Cancer 54:2706–2715
Schmaehl D, Petru E (1989) Cancer chemotherapy: current status and selected aspects of new drug development. Science Interdisc Rev 14:284–290
Schwartz P, Smith J (1980) Second-look operations in ovarian cancer. Am J Obstet Gynecol 138:1124–1130
Sevin BU, Peng Z, Perras J, Ganjei P, Penalver M, Averette H (1988) Application of an ATP-bioluminescence assay in human tumor chemosensitivity testing. Gynecol Oncol 31:191–204
Smith J, Day T (1979) Review of ovarian cancer at the University of Texas Systems Cancer Center, M.D. Anderson Hospital and Tumor Institute. Am J Obstet Gynecol 135:984–990
Sutton G, Stehman F, Einhorn L, Roth L, Blessing J, Ehrlich C (1989) Ten-year follow-up of patients receiving cisplatin, doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma. J Clin Oncol 7:223–229
Wharton J, Edwards C, Rutledge F (1984) Long-term survival after chemotherapy for advanced epithelial ovarian carcinoma. Am J Obstet Gynecol 148:997–1004
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Petru, E., Sevin, B.U., Averette, H.E. et al. Long-term survival in stage III and IV ovarian cancer. Arch Gynecol Obstet 249, 87–93 (1991). https://doi.org/10.1007/BF02390367
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02390367